These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 32127409)

  • 1. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
    Najafian B; Tøndel C; Svarstad E; Gubler MC; Oliveira JP; Mauer M
    J Am Soc Nephrol; 2020 Apr; 31(4):865-875. PubMed ID: 32127409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.
    Najafian B; Tøndel C; Svarstad E; Sokolovkiy A; Smith K; Mauer M
    PLoS One; 2016; 11(4):e0152812. PubMed ID: 27081853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.
    Najafian B; Svarstad E; Bostad L; Gubler MC; Tøndel C; Whitley C; Mauer M
    Kidney Int; 2011 Mar; 79(6):663-670. PubMed ID: 21160462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.
    Najafian B; Silvestroni A; Sokolovskiy A; Tøndel C; Svarstad E; Obrisca B; Ismail G; Holida MD; Mauer M
    Kidney Int; 2022 Jul; 102(1):173-182. PubMed ID: 35483528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
    Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
    Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
    Skrunes R; Svarstad E; Kampevold Larsen K; Leh S; Tøndel C
    Nephrol Dial Transplant; 2017 May; 32(5):807-813. PubMed ID: 27190352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.
    Mauer M; Glynn E; Svarstad E; Tøndel C; Gubler MC; West M; Sokolovskiy A; Whitley C; Najafian B
    PLoS One; 2014; 9(11):e112188. PubMed ID: 25386848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
    Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedside Stereomicroscopy of Fabry Kidney Biopsies: An Easily Available Method for Diagnosis and Assessment of Sphingolipid Deposits.
    Svarstad E; Leh S; Skrunes R; Kampevold Larsen K; Eikrem Ø; Tøndel C
    Nephron; 2018; 138(1):13-21. PubMed ID: 28848191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
    Braun F; Abed A; Sellung D; Rogg M; Woidy M; Eikrem O; Wanner N; Gambardella J; Laufer SD; Haas F; Wong MN; Dumoulin B; Rischke P; Mühlig A; Sachs W; von Cossel K; Schulz K; Muschol N; Gersting SW; Muntau AC; Kretz O; Hahn O; Rinschen MM; Mauer M; Bork T; Grahammer F; Liang W; Eierhoff T; Römer W; Hansen A; Meyer-Schwesinger C; Iaccarino G; Tøndel C; Marti HP; Najafian B; Puelles VG; Schell C; Huber TB
    J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37014703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
    Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
    Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.
    Fall B; Scott CR; Mauer M; Shankland S; Pippin J; Jefferson JA; Wallace E; Warnock D; Najafian B
    PLoS One; 2016; 11(12):e0168346. PubMed ID: 27992580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased urinary CD80 excretion and podocyturia in Fabry disease.
    Trimarchi H; Canzonieri R; Schiel A; Costales-Collaguazo C; Politei J; Stern A; Paulero M; Rengel T; Andrews J; Forrester M; Lombi M; Pomeranz V; Iriarte R; Muryan A; Zotta E; Sanchez-Niño MD; Ortiz A
    J Transl Med; 2016 Oct; 14(1):289. PubMed ID: 27733175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective.
    Hodgin JB; Bitzer M; Wickman L; Afshinnia F; Wang SQ; O'Connor C; Yang Y; Meadowbrooke C; Chowdhury M; Kikuchi M; Wiggins JE; Wiggins RC
    J Am Soc Nephrol; 2015 Dec; 26(12):3162-78. PubMed ID: 26038526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease.
    Prabakaran T; Nielsen R; Larsen JV; Sørensen SS; Feldt-Rasmussen U; Saleem MA; Petersen CM; Verroust PJ; Christensen EI
    PLoS One; 2011; 6(9):e25065. PubMed ID: 21949853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).
    Fogo AB; Bostad L; Svarstad E; Cook WJ; Moll S; Barbey F; Geldenhuys L; West M; Ferluga D; Vujkovac B; Howie AJ; Burns A; Reeve R; Waldek S; Noël LH; Grünfeld JP; Valbuena C; Oliveira JP; Müller J; Breunig F; Zhang X; Warnock DG;
    Nephrol Dial Transplant; 2010 Jul; 25(7):2168-77. PubMed ID: 19833663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated autophagy contributes to podocyte damage in Fabry's disease.
    Liebau MC; Braun F; Höpker K; Weitbrecht C; Bartels V; Müller RU; Brodesser S; Saleem MA; Benzing T; Schermer B; Cybulla M; Kurschat CE
    PLoS One; 2013; 8(5):e63506. PubMed ID: 23691056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease.
    Kim IY; Lee HJ; Cheon CK
    Kidney Res Clin Pract; 2021 Dec; 40(4):611-619. PubMed ID: 34922431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.